Poly(ADP-Ribose) Polymerases: Homology, Structural Domains and Functions. Novel Therapeutical Applications
Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes, which show differences in structure, cellular location and functions. However, all these enzymes possess poly(ADP-ribosyl)ation activity. Overactivation of PARP enzymes has been implicated in the pathogenesis of several diseases, includin...
Gespeichert in:
| Veröffentlicht in: | Progress in Biophysics and Molecular Biology 2005-05, Vol.88 (1), p.143-172 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 172 |
|---|---|
| container_issue | 1 |
| container_start_page | 143 |
| container_title | Progress in Biophysics and Molecular Biology |
| container_volume | 88 |
| creator | Nguewa, Paul A. Fuertes, Miguel A. Valladares, Basilio Alonso, Carlos Pérez, José M. |
| description | Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes, which show differences in structure, cellular location and functions. However, all these enzymes possess poly(ADP-ribosyl)ation activity. Overactivation of PARP enzymes has been implicated in the pathogenesis of several diseases, including stroke, myocardial infarction, diabetes, shock, neurodegenerative disorder and allergy. The best studied of these enzymes (PARP-1) is involved in the cellular response to DNA damage so that in the event of irreparable DNA damage overactivation of PARP-1 leads to necrotic cell death. Inhibitors of PARP-1 activity in combination with DNA-binding antitumor drugs may constitute a suitable strategy in cancer chemotherapy. In addition, PARP inhibitors may be also useful to restore cellular functions in several pathophysiological states and diseases. This review gives an update of the state-of-the-art concerning PARP enzymes and their exploitation as pharmacological targets in several illnesses. |
| doi_str_mv | 10.1016/j.pbiomolbio.2004.01.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67262726</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0079610704000057</els_id><sourcerecordid>67262726</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486t-6fbc0188b579f2f4cdfa1f50770a71f5dba24d4cf33a103c9cda4227b1558f283</originalsourceid><addsrcrecordid>eNqFkFFLwzAUhYMobk7_guRJFGy9Sbum821u6gRR0fkc0jTRjLapSSvs35u5gY8-3NxL-M493IMQJhATINnVKm4LY2tbhTemAGkMJAYge2hIcpZEhCV0Hw0B2CTKCLABOvJ-BQCUsOwQDch4nJEEkiFavdhqfT6dv0SvprBeXeDNR62c8Mpf48XGxH6sL_Fb53rZ9U5UeG5rYRqPRVPiu76RnbGNj_GT_VYVXn4Gbav6zsiATtu2CsMvcYwOtKi8Otn1EXq_u13OFtHj8_3DbPoYyTTPuijThQSS58WYTTTVqSy1IHoMjIFgYSgLQdMylTpJBIFETmQpUkpZEY7KNc2TETrb7m2d_eqV73htvFRVJRple88zRjMaKoD5FpTOeu-U5q0ztXBrToBvcuYr_pcz3-TMgfCQc5Ce7jz6olbln3AXbAButoAKl34b5biXRjVSlcYp2fHSmv9dfgAbZ5U1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67262726</pqid></control><display><type>article</type><title>Poly(ADP-Ribose) Polymerases: Homology, Structural Domains and Functions. Novel Therapeutical Applications</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Nguewa, Paul A. ; Fuertes, Miguel A. ; Valladares, Basilio ; Alonso, Carlos ; Pérez, José M.</creator><creatorcontrib>Nguewa, Paul A. ; Fuertes, Miguel A. ; Valladares, Basilio ; Alonso, Carlos ; Pérez, José M.</creatorcontrib><description>Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes, which show differences in structure, cellular location and functions. However, all these enzymes possess poly(ADP-ribosyl)ation activity. Overactivation of PARP enzymes has been implicated in the pathogenesis of several diseases, including stroke, myocardial infarction, diabetes, shock, neurodegenerative disorder and allergy. The best studied of these enzymes (PARP-1) is involved in the cellular response to DNA damage so that in the event of irreparable DNA damage overactivation of PARP-1 leads to necrotic cell death. Inhibitors of PARP-1 activity in combination with DNA-binding antitumor drugs may constitute a suitable strategy in cancer chemotherapy. In addition, PARP inhibitors may be also useful to restore cellular functions in several pathophysiological states and diseases. This review gives an update of the state-of-the-art concerning PARP enzymes and their exploitation as pharmacological targets in several illnesses.</description><identifier>ISSN: 0079-6107</identifier><identifier>EISSN: 1873-1732</identifier><identifier>DOI: 10.1016/j.pbiomolbio.2004.01.001</identifier><identifier>PMID: 15561303</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Cell Death - physiology ; DNA Damage - physiology ; DNA Repair - physiology ; Enzyme Inhibitors - pharmacology ; Functions ; Humans ; Location ; Neoplasms - drug therapy ; Nervous System Diseases - drug therapy ; New therapies ; PARP polymerases ; Poly(ADP-ribose) Polymerase Inhibitors ; Poly(ADP-ribose) Polymerases - metabolism ; Structure</subject><ispartof>Progress in Biophysics and Molecular Biology, 2005-05, Vol.88 (1), p.143-172</ispartof><rights>2004 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486t-6fbc0188b579f2f4cdfa1f50770a71f5dba24d4cf33a103c9cda4227b1558f283</citedby><cites>FETCH-LOGICAL-c486t-6fbc0188b579f2f4cdfa1f50770a71f5dba24d4cf33a103c9cda4227b1558f283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0079610704000057$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>313,314,776,780,788,3537,27899,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15561303$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nguewa, Paul A.</creatorcontrib><creatorcontrib>Fuertes, Miguel A.</creatorcontrib><creatorcontrib>Valladares, Basilio</creatorcontrib><creatorcontrib>Alonso, Carlos</creatorcontrib><creatorcontrib>Pérez, José M.</creatorcontrib><title>Poly(ADP-Ribose) Polymerases: Homology, Structural Domains and Functions. Novel Therapeutical Applications</title><title>Progress in Biophysics and Molecular Biology</title><addtitle>Prog Biophys Mol Biol</addtitle><description>Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes, which show differences in structure, cellular location and functions. However, all these enzymes possess poly(ADP-ribosyl)ation activity. Overactivation of PARP enzymes has been implicated in the pathogenesis of several diseases, including stroke, myocardial infarction, diabetes, shock, neurodegenerative disorder and allergy. The best studied of these enzymes (PARP-1) is involved in the cellular response to DNA damage so that in the event of irreparable DNA damage overactivation of PARP-1 leads to necrotic cell death. Inhibitors of PARP-1 activity in combination with DNA-binding antitumor drugs may constitute a suitable strategy in cancer chemotherapy. In addition, PARP inhibitors may be also useful to restore cellular functions in several pathophysiological states and diseases. This review gives an update of the state-of-the-art concerning PARP enzymes and their exploitation as pharmacological targets in several illnesses.</description><subject>Cell Death - physiology</subject><subject>DNA Damage - physiology</subject><subject>DNA Repair - physiology</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Functions</subject><subject>Humans</subject><subject>Location</subject><subject>Neoplasms - drug therapy</subject><subject>Nervous System Diseases - drug therapy</subject><subject>New therapies</subject><subject>PARP polymerases</subject><subject>Poly(ADP-ribose) Polymerase Inhibitors</subject><subject>Poly(ADP-ribose) Polymerases - metabolism</subject><subject>Structure</subject><issn>0079-6107</issn><issn>1873-1732</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkFFLwzAUhYMobk7_guRJFGy9Sbum821u6gRR0fkc0jTRjLapSSvs35u5gY8-3NxL-M493IMQJhATINnVKm4LY2tbhTemAGkMJAYge2hIcpZEhCV0Hw0B2CTKCLABOvJ-BQCUsOwQDch4nJEEkiFavdhqfT6dv0SvprBeXeDNR62c8Mpf48XGxH6sL_Fb53rZ9U5UeG5rYRqPRVPiu76RnbGNj_GT_VYVXn4Gbav6zsiATtu2CsMvcYwOtKi8Otn1EXq_u13OFtHj8_3DbPoYyTTPuijThQSS58WYTTTVqSy1IHoMjIFgYSgLQdMylTpJBIFETmQpUkpZEY7KNc2TETrb7m2d_eqV73htvFRVJRple88zRjMaKoD5FpTOeu-U5q0ztXBrToBvcuYr_pcz3-TMgfCQc5Ce7jz6olbln3AXbAButoAKl34b5biXRjVSlcYp2fHSmv9dfgAbZ5U1</recordid><startdate>20050501</startdate><enddate>20050501</enddate><creator>Nguewa, Paul A.</creator><creator>Fuertes, Miguel A.</creator><creator>Valladares, Basilio</creator><creator>Alonso, Carlos</creator><creator>Pérez, José M.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050501</creationdate><title>Poly(ADP-Ribose) Polymerases: Homology, Structural Domains and Functions. Novel Therapeutical Applications</title><author>Nguewa, Paul A. ; Fuertes, Miguel A. ; Valladares, Basilio ; Alonso, Carlos ; Pérez, José M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486t-6fbc0188b579f2f4cdfa1f50770a71f5dba24d4cf33a103c9cda4227b1558f283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Cell Death - physiology</topic><topic>DNA Damage - physiology</topic><topic>DNA Repair - physiology</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Functions</topic><topic>Humans</topic><topic>Location</topic><topic>Neoplasms - drug therapy</topic><topic>Nervous System Diseases - drug therapy</topic><topic>New therapies</topic><topic>PARP polymerases</topic><topic>Poly(ADP-ribose) Polymerase Inhibitors</topic><topic>Poly(ADP-ribose) Polymerases - metabolism</topic><topic>Structure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nguewa, Paul A.</creatorcontrib><creatorcontrib>Fuertes, Miguel A.</creatorcontrib><creatorcontrib>Valladares, Basilio</creatorcontrib><creatorcontrib>Alonso, Carlos</creatorcontrib><creatorcontrib>Pérez, José M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Progress in Biophysics and Molecular Biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nguewa, Paul A.</au><au>Fuertes, Miguel A.</au><au>Valladares, Basilio</au><au>Alonso, Carlos</au><au>Pérez, José M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Poly(ADP-Ribose) Polymerases: Homology, Structural Domains and Functions. Novel Therapeutical Applications</atitle><jtitle>Progress in Biophysics and Molecular Biology</jtitle><addtitle>Prog Biophys Mol Biol</addtitle><date>2005-05-01</date><risdate>2005</risdate><volume>88</volume><issue>1</issue><spage>143</spage><epage>172</epage><pages>143-172</pages><issn>0079-6107</issn><eissn>1873-1732</eissn><abstract>Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes, which show differences in structure, cellular location and functions. However, all these enzymes possess poly(ADP-ribosyl)ation activity. Overactivation of PARP enzymes has been implicated in the pathogenesis of several diseases, including stroke, myocardial infarction, diabetes, shock, neurodegenerative disorder and allergy. The best studied of these enzymes (PARP-1) is involved in the cellular response to DNA damage so that in the event of irreparable DNA damage overactivation of PARP-1 leads to necrotic cell death. Inhibitors of PARP-1 activity in combination with DNA-binding antitumor drugs may constitute a suitable strategy in cancer chemotherapy. In addition, PARP inhibitors may be also useful to restore cellular functions in several pathophysiological states and diseases. This review gives an update of the state-of-the-art concerning PARP enzymes and their exploitation as pharmacological targets in several illnesses.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>15561303</pmid><doi>10.1016/j.pbiomolbio.2004.01.001</doi><tpages>30</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0079-6107 |
| ispartof | Progress in Biophysics and Molecular Biology, 2005-05, Vol.88 (1), p.143-172 |
| issn | 0079-6107 1873-1732 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67262726 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Cell Death - physiology DNA Damage - physiology DNA Repair - physiology Enzyme Inhibitors - pharmacology Functions Humans Location Neoplasms - drug therapy Nervous System Diseases - drug therapy New therapies PARP polymerases Poly(ADP-ribose) Polymerase Inhibitors Poly(ADP-ribose) Polymerases - metabolism Structure |
| title | Poly(ADP-Ribose) Polymerases: Homology, Structural Domains and Functions. Novel Therapeutical Applications |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T20%3A46%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Poly(ADP-Ribose)%20Polymerases:%20Homology,%20Structural%20Domains%20and%20Functions.%20Novel%20Therapeutical%20Applications&rft.jtitle=Progress%20in%20Biophysics%20and%20Molecular%20Biology&rft.au=Nguewa,%20Paul%20A.&rft.date=2005-05-01&rft.volume=88&rft.issue=1&rft.spage=143&rft.epage=172&rft.pages=143-172&rft.issn=0079-6107&rft.eissn=1873-1732&rft_id=info:doi/10.1016/j.pbiomolbio.2004.01.001&rft_dat=%3Cproquest_cross%3E67262726%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67262726&rft_id=info:pmid/15561303&rft_els_id=S0079610704000057&rfr_iscdi=true |